Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Australian Patent Granted for NUZ-001 for Neurodegenerative Diseases

Highlights:

- **Australian patent granted covering NUZ-001 for the treatment of neurodegenerative diseases including ALS/MND and others such as Alzheimer's disease, Huntington's disease and Parkinson's disease**
- **Complements the expedited US patent grant issued earlier this year and provides unified runway through to May 2041 across major global markets**
- **Patent grant further strengthens global IP portfolio and ongoing work to support NUZ-001 expanded commercialisation opportunities**
- **Company remains well placed to unlock value from NUZ-001 through entry into HEALEY ALS Platform Trial this quarter**

21 October 2025 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise it has received notice from the Australian Patent Office, informing the grant of a new patent entitled "Use of aminoacetonitrile compounds for the treatment of infection and disease" (patent number 2021272252).

This method of use patent extends protection for Neurizon's lead drug candidate, NUZ-001, and related compounds across key therapeutic areas, including mTOR-pathway related diseases, such as ALS/MND, along with various other neurodegenerative diseases, in particular Alzheimer's disease, Huntington's disease and Parkinson's disease, as well as cancer and infectious diseases.

This newly granted patent complements Neurizon's existing US Patent for NUZ-001 in neurodegenerative diseases and cancer (refer ASX announcement: 5 February 2025) and ensures unified intellectual property (IP) protection through to May 2041 across major global markets.

The Company continues to advance a number of clinical development and commercialisation opportunities for NUZ-001, including entry into the HEALEY ALS Platform Trial expected later this year. Trial entry will be undertaken alongside a range of other initiatives, including ongoing partnerships, licensing and platform therapy development strategies across multiple disease areas.

Managing Director and Chief Executive Officer, Dr Michael Thurn commented: "Securing this additional Australian patent was a priority for the management team. It further strengthens our global intellectual property position for NUZ-001 and provides long-term protection across our core markets and a strong foundation for expanding our therapeutic pipeline. With this protection in place, we are ideally positioned to leverage Australia's exceptional early-phase clinical trial capabilities to accelerate development. At the same time, we remain fully committed to our pre-clinical program, showcasing NUZ-001's promise as a platform molecule with potential to address a range of neurodegenerative diseases that currently lack effective treatment options."

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited.